Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the partnership, Synaptogenix obtains a preemptive right to fund the further research and commercialization of certain intellectual property, technology, and for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications.
Lead Product(s): Cannabinoid-based Therapeutic
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Synaptogenix
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Partnership November 02, 2023